[MO31] Mini-Oral Session 31　Clinical Trial Facilitation Program 1（Trial in Progress）

[MO31-3] Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): A Phase 2 Study (DESTINY-Lung02)

^○Koichi Goto¹, Egbert F. Smit², Bob T. Li³, Julian Mazieres⁴, David Planchard⁵, Kazuhiko Nakagawa⁶, Luis Paz-Ares⁷, Silvia Novello⁸, James Chih-Hsin Yang⁹, Myung-Ju Ahn¹⁰, Geoffrey Liu¹¹, Kenneth O’Byrne¹², Mehreteab Aregay¹³, Ryota Shiga¹³, Kapil Saxena¹³, Kaline Pereira¹³, Gerold Meinhardt¹³, Pasi A. Janne¹⁴ (1.National Cancer Center Hospital East, Kashiwa, Japan, 2.Netherlands Cancer Institute, Amsterdam, Netherlands, 3.Memorial Sloan Kettering Cancer Center, New York, NY, USA, 4.Institut Universitaire du Cancer, Toulouse, France, 5.Gustave Roussy, Villejuif, France, 6.Kindai University Hospital, Osaka, Japan, 7.Hospital Universitario 12 de Octubre, Madrid, Spain, 8.University of Turin, AOU San Luigi-Orbassano (TO), Orbassano, Italy, 9.National Taiwan University Cancer Center, Taipei, Taiwan, 10.Samsung Medical Center, Seoul, South Korea, 11.Princess Margaret Cancer Centre, Toronto, ON, Canada, 12.Princess Alexandra Hospital, Brisbane, QLD, Australia, 13.Daiichi Sankyo, Inc., Basking Ridge, NJ, USA, 14.Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, USA)